Trimb acquires OTC products from CCS

Trimb Healthcare AB (“Trimb”) has acquired CCS Healthcare AB’s ("CCS") OTC drugs in the Nordic region. The products, including Cortimyk (treatment of athlete’s foot), Hydrocortisone CCS (treatment of eczema) and Propyless (treatment of dry skin) are well-established on their markets and generate total annual sales of about EUR 10 million.

"Trimb already has strong organic sales growth in the Nordic region and in other North European markets. The acquisition of the CCS portfolio strengthens our position in dermatology and expands our portfolio for the future,” says Magnus Kamryd, CEO of Trimb.

The purchase price, which is not public, is fully covered by Trimb’s principal investor, Avista Capital Partners, a leading private equity company.

For more information, please contact:
Anders Larnholt, VP M & A Trimb
Phone: +46 (0)76 677 64 95